Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

In vivo drug interactions of the teratogen thalidomide with midazolam: heterotropic cooperativity of human cytochrome P450 in humanized TK-NOG mice.

Yamazaki H, Suemizu H, Murayama N, Utoh M, Shibata N, Nakamura M, Guengerich FP.

Chem Res Toxicol. 2013 Mar 18;26(3):486-9. doi: 10.1021/tx400008g. Epub 2013 Mar 1.

2.

Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5.

Okada Y, Murayama N, Yanagida C, Shimizu M, Guengerich FP, Yamazaki H.

Drug Metab Dispos. 2009 Jan;37(1):18-23. doi: 10.1124/dmd.108.024679. Epub 2008 Oct 23.

3.

Thalidomide increases human hepatic cytochrome P450 3A enzymes by direct activation of the pregnane X receptor.

Murayama N, van Beuningen R, Suemizu H, Guillouzo CG, Shibata N, Yajima K, Utoh M, Shimizu M, Chesné C, Nakamura M, Guengerich FP, Houtman R, Yamazaki H.

Chem Res Toxicol. 2014 Feb 17;27(2):304-308. doi: 10.1021/tx4004374. Epub 2014 Feb 5.

4.

Simulation of Human Plasma Concentrations of Thalidomide and Primary 5-Hydroxylated Metabolites Explored with Pharmacokinetic Data in Humanized TK-NOG Mice.

Nishiyama S, Suemizu H, Shibata N, Guengerich FP, Yamazaki H.

Chem Res Toxicol. 2015 Nov 16;28(11):2088-90. doi: 10.1021/acs.chemrestox.5b00381. Epub 2015 Oct 26.

PMID:
26492539
5.

Induction of human cytochrome P450 3A enzymes in cultured placental cells by thalidomide and relevance to bioactivation and toxicity.

Murayama N, Kazuki Y, Satoh D, Arata K, Harada T, Shibata N, Guengerich FP, Yamazaki H.

J Toxicol Sci. 2017;42(3):343-348. doi: 10.2131/jts.42.343.

6.

Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam.

Katzenmaier S, Markert C, Mikus G.

Eur J Clin Pharmacol. 2010 Nov;66(11):1137-41. doi: 10.1007/s00228-010-0878-2. Epub 2010 Aug 3.

PMID:
20680253
7.

In vivo formation of dihydroxylated and glutathione conjugate metabolites derived from thalidomide and 5-Hydroxythalidomide in humanized TK-NOG mice.

Yamazaki H, Suemizu H, Shimizu M, Igaya S, Shibata N, Nakamura M, Chowdhury G, Guengerich FP.

Chem Res Toxicol. 2012 Feb 20;25(2):274-6. doi: 10.1021/tx300009j. Epub 2012 Jan 25.

9.

Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.

Villeneuve JP, L'Ecuyer L, De Maeght S, Bannon P.

Clin Pharmacol Ther. 2000 Mar;67(3):242-8.

PMID:
10741627
10.
11.

A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions.

Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE.

Clin Pharmacol Ther. 2013 Jun;93(6):564-71. doi: 10.1038/clpt.2013.27. Epub 2013 Feb 8.

PMID:
23511711
12.

The effect of ticagrelor on the metabolism of midazolam in healthy volunteers.

Teng R, Butler K.

Clin Ther. 2013 Jul;35(7):1025-37. doi: 10.1016/j.clinthera.2013.06.003.

PMID:
23870610
13.

Heterotropic activation of the midazolam hydroxylase activity of CYP3A by a positive allosteric modulator of mGlu5: in vitro to in vivo translation and potential impact on clinically relevant drug-drug interactions.

Blobaum AL, Bridges TM, Byers FW, Turlington ML, Mattmann ME, Morrison RD, Mackie C, Lavreysen H, Bartolomé JM, Macdonald GJ, Steckler T, Jones CK, Niswender CM, Conn PJ, Lindsley CW, Stauffer SR, Daniels JS.

Drug Metab Dispos. 2013 Dec;41(12):2066-75. doi: 10.1124/dmd.113.052662. Epub 2013 Sep 3.

14.

Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.

Yamazaki H, Suemizu H, Mitsui M, Shimizu M, Guengerich FP.

Chem Res Toxicol. 2016 Dec 19;29(12):1903-1911. Epub 2016 Jul 5. Review.

15.

Thalidomide-induced limb abnormalities in a humanized CYP3A mouse model.

Kazuki Y, Akita M, Kobayashi K, Osaki M, Satoh D, Ohta R, Abe S, Takehara S, Kazuki K, Yamazaki H, Kamataki T, Oshimura M.

Sci Rep. 2016 Feb 23;6:21419. doi: 10.1038/srep21419.

16.

Role of temperature on protein and mRNA cytochrome P450 3A (CYP3A) isozymes expression and midazolam oxidation by cultured rat precision-cut liver slices.

Rekka E, Evdokimova E, Eeckhoudt S, Labar G, Calderon PB.

Biochem Pharmacol. 2002 Aug 15;64(4):633-43.

PMID:
12167482
17.

Reversible, time-dependent inhibition of CYP3A-mediated metabolism of midazolam and tacrolimus by telaprevir in human liver microsomes.

Chapron B, Risler L, Phillips B, Collins C, Thummel K, Shen D.

J Pharm Pharm Sci. 2015;18(1):101-11.

18.

Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.

Yang J, Atkins WM, Isoherranen N, Paine MF, Thummel KE.

Clin Pharmacol Ther. 2012 Mar;91(3):442-9. doi: 10.1038/clpt.2011.178. Epub 2011 Nov 2.

19.

The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4.

Roberts AG, Yang J, Halpert JR, Nelson SD, Thummel KT, Atkins WM.

Biochemistry. 2011 Dec 20;50(50):10804-18. doi: 10.1021/bi200924t. Epub 2011 Nov 22. Erratum in: Biochemistry. 2012 Feb 14;51(6):1332.

20.

Supplemental Content

Support Center